Ibucare

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibucare

What is Ibucare?

Ibucare is a medicinal product categorized as a non-steroidal anti-inflammatory drug (NSAID). It contains the active substance ibuprofen, which belongs to a class of compounds used for their analgesic, antipyretic, and anti-inflammatory properties.

Mechanism of Action

The active ingredient in Ibucare works by inhibiting the activity of enzymes known as cyclooxygenases (COX-1 and COX-2). These enzymes play a central role in the production of prostaglandins, which are lipid compounds in the body that act as mediators for pain and inflammation signals. By reducing the synthesis of these prostaglandins, the medication helps to decrease the sensation of pain and lower elevated body temperatures.

General Characteristics

Ibucare is typically utilized to manage various types of mild to moderate pain and to reduce fever. As an NSAID, it is part of a broad group of medications frequently used in clinical practice for the symptomatic relief of conditions involving inflammation or physical discomfort.

Therapeutic Intent

The primary purpose of Ibucare is to provide temporary relief from symptoms rather than treating an underlying chronic condition. It is formulated to be absorbed into the bloodstream to reach the site of discomfort or to act systemically to regulate temperature.

Regulatory References

  1. WHO Essential Medicines List: Ibuprofen
  2. NIH NSAID Information

What side effects are possible with Ibucare?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Ibucare based on System-Organ Classes and frequency of occurrence. The most critical safety information is structured around potential serious adverse events and specific population restrictions.


Serious and Clinically Significant Risks

Government authorities mandate warnings regarding two primary serious risks associated with Ibucare use:

  • Cardiovascular Thrombotic Events: Increased risk of serious events such as myocardial infarction (heart attack) and stroke, which can be fatal. This risk may occur early in treatment and may increase with both higher doses and longer duration of use.
  • Gastrointestinal Adverse Events: Risk of serious gastrointestinal inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can also be fatal. This risk is higher in elderly patients and those with a prior history of GI disease, and generally increases with dose and duration.

Adverse Reaction Classification

Reported adverse reactions range from common to rare and typically involve several body systems:

  • Gastrointestinal Disorders: The most frequently reported class, including indigestion, nausea, vomiting, and abdominal pain.
  • Nervous System Disorders: Commonly reported reactions include headache and dizziness.
  • Hypersensitivity Reactions: Potential for serious, sometimes fatal, allergic reactions (including anaphylaxis), particularly in individuals with a known aspirin or NSAID sensitivity.

Population-Specific Safety Notes

Specific restrictions and cautions are formally documented for certain groups:

  • Pregnancy: Use is generally contraindicated during the third trimester due to potential harm to the fetus.
  • Elderly Patients: Require particular caution due to a higher frequency of serious gastrointestinal bleeding and kidney-related adverse effects.

Safety Limitations

Ibucare is contraindicated for the treatment of pain immediately following coronary artery bypass graft (CABG) surgery and in patients with active gastrointestinal bleeding or ulceration. Caution is required when used concurrently with other medicines that affect blood clotting (e.g., anticoagulants).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Ibuprofen overdose defines the clinical presentation of acute toxicity and the required emergency response. Overdose may initially present with common signs affecting the gastrointestinal and central nervous systems. Documented manifestations include nausea, vomiting, epigastric pain, headache, dizziness, ringing in the ears (tinnitus), drowsiness, confusion, and lethargy. These are the typical initial presentations noted in official prescribing information.

Immediate medical attention must be sought in all suspected overdose scenarios. Authorities require contacting emergency services or a poison control center right away, as severe outcomes may occur rapidly. The official labeling describes the potential for serious complications such as acute renal failure, metabolic acidosis, severe hypotension, seizures, coma, and life-threatening gastrointestinal bleeding or perforation.

There is no specific antidote known for Ibuprofen overdose. Management is officially restricted to symptomatic and supportive treatment. This may include clinical procedures like administering activated charcoal and continuous monitoring of vital signs and laboratory parameters in a hospital setting. Regulatory notes indicate that pediatric risk is stratified based on the dose ingested, and elderly patients face an increased risk for severe gastrointestinal events following acute toxicity.

Therapeutic Uses of Ibucare

Ibucare is relevant in contexts marked by increased discomfort and may be part of symptomatic management across multiple therapeutic domains. It is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort, systemic imbalance, and inflammatory states. It is commonly used to help with easing symptoms such as minor aches and pains, headache, muscular aches, toothache, and menstrual cramps, as well as temporarily reducing fever.

It is commonly used to help with conditions presenting with acute episodes and recurrent manifestations, including musculoskeletal pain, rheumatoid disorders like osteoarthritis, fever associated with cold or flu, and primary dysmenorrhea.

“It supports the patient during difficult episodes by easing distress and is helpful when symptoms create noticeable physiological strain.”

This use is generally relevant when short-term symptomatic assistance is needed, such as during phases when symptoms become more noticeable or relevant in contexts involving heightened systemic burden. The medication offers symptomatic relief that **may help patients cope more steadily with symptom fluctuations.


Therapeutic Focus: Pain, Fever, and Inflammation

The medication is commonly used to address the triple symptom cluster of pain, fever, and inflammation, offering supportive relief during periods of heightened symptoms.

Eligibility and Restrictions for Use

Population Eligibility for Ibucare (Ibuprofen)

Official regulatory documents define who can and cannot use Ibucare, establishing specific restrictions and contraindications based on patient status, age, and pre-existing health conditions.

Contraindications (Must Not Use)

Ibucare is contraindicated and must not be used by patients with a known hypersensitivity to Ibuprofen or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin. It is also prohibited for patients with active or a history of recurrent peptic ulcer or gastrointestinal hemorrhage. Absolute contraindications further include those in the setting of coronary artery bypass graft (CABG) surgery, severe heart failure (NYHA Class IV), severe renal impairment, or severe hepatic insufficiency. Use is strictly prohibited during the third trimester of pregnancy.


Conditional and Age-Related Use

Use requires caution in patients with mild to moderate hepatic or renal impairment, and in those with pre-existing cardiovascular risk factors such as uncontrolled hypertension. The pediatric population is eligible, typically starting from 3 to 6 months of age depending on the formulation. Older adults (geriatric) require use of the lowest effective dose for the shortest duration due to increased risks. Use during the first and second trimesters of pregnancy is generally not recommended unless considered essential. Ibucare is generally considered acceptable for short-term, low-dose use during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ibucare documents multiple interaction patterns. Co-administration is contraindicated with other nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors, due to the increased risk of serious gastrointestinal events. Ibuprofen is also contraindicated for peri-operative pain after Coronary Artery Bypass Graft (CABG) surgery.

The drug exhibits significant Pharmacodynamic (PD) interactions that heighten bleeding risk. Concomitant use with Anticoagulants (e.g., Warfarin) and other Antiplatelet agents is documented as increasing the risk of hemorrhage. Similarly, combining with Corticosteroids or SSRIs (Selective Serotonin Reuptake Inhibitors) elevates the documented risk of gastrointestinal bleeding.

A primary Pharmacokinetic (PK) pattern involves Ibuprofen reducing the renal clearance of substances with narrow therapeutic ranges, such as Lithium and Methotrexate, leading to officially elevated plasma concentrations of these co-administered drugs. Regulatory labels state that CYP2C9 inhibitors, such as Fluconazole, will increase the systemic exposure of Ibuprofen.

For patients using low-dose Aspirin for antiplatelet effect, the regulatory guidance suggests a timing separation: Ibuprofen should be administered at least 8 hours before or 30 minutes after immediate-release low-dose Aspirin. Alcohol intake is documented as an additional factor that increases the risk of gastrointestinal bleeding.

Mechanism of Action

Modulation of Eicosanoid Pathways

Ibuprofen acts as an inhibitor within enzyme-mediated signaling systems by targeting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This mechanism interrupts the conversion of arachidonic acid to downstream signaling molecules. Inhibition of these enzymes blocks the metabolic cascade that generates prostaglandins and thromboxanes, which are eicosanoid mediators. This process reduces the local concentration of these potent signaling molecules at the site of synthesis, thereby modifying cellular communication and limiting the activation of specific inflammatory pathways.


Central Nervous System Muscle Regulation

Chlorzoxazone engages mechanisms that influence centers in the central nervous system (CNS) responsible for motor control and resting muscle tone. The compound primarily targets descending polysynaptic pathways within the spinal cord and subcortical areas. Its action on these pathways results in a reduction of hyperactivity in motor neurons. This systemic modulation decreases involuntary firing, which ultimately affects the control of peripheral muscle tone.

Dosage and Administration Information

How to Use Ibucare: Administration Guidelines

This section outlines the instructions for the administration and dosing of ibuprofen (often branded as Ibucare) as detailed in standard health documentation and medicinal labeling.

Administration and Dosing Instructions

Administration Element Standard Rule
Route(s) of Administration Oral (Tablet, Capsule, Suspension), Topical (Gel/Cream), Rectal (Suppository).
Standard Adult Oral Dose 200 mg to 400 mg per dose.
Frequency Doses may be repeated every 4 to 6 hours as needed.
Maximum Daily Dose (Adult) Must not exceed the prescription or over-the-counter limit (e.g., 1200 mg or 3200 mg, depending on form and regulation).
Relation to Meals May be taken with food or milk if stomach upset occurs.
Liquid Preparation Oral suspensions must be shaken well before measuring. Use a calibrated dosing device for accuracy.

Population-Specific and Duration Rules

  • Pediatric Patients: Dosing for children is calculated based on body weight (mg/kg) or age, utilizing appropriate liquid or chewable forms. Consult standard pediatric dosing tables.
  • Geriatric Patients: Dosing may require starting at the lower end of the adult range.
  • Duration Limit for Self-Care: Labeling mandates that self-treatment must not exceed 10 days for pain or 3 days for fever unless explicitly directed by a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ibucare

Evidence for Symptomatic Relief of Acute Pain and Headache

Research has explored Ibucare for acute pain and headache, focusing on outcomes related to measured pain intensity. These studies were conducted during episodes where symptoms become more noticeable, exploring how symptoms change over defined time intervals. The research primarily consists of short-term Randomized Controlled Trials (RCTs) and Meta-analyses that examined measures of mild-to-moderate acute pain in adults and adolescents.

Studies reported measurements related to changes in self-reported pain intensity across various short-term acute pain models. Reports described patterns related to the onset of action and the duration of measured symptom change following a single dose. However, the existing studies provide limited information for long-term outcomes when research scenarios involving recurring acute pain are considered, and data for severe acute pain appears to be limited.


Evidence for Exploring Fever and Primary Dysmenorrhea

Ibucare was studied for its use as an antipyretic agent and for research exploring primary dysmenorrhea (menstrual pain), both conditions characterized by fluctuating or episodic manifestations. For research exploring fever, studies monitored outcomes related to changes in body temperature. For primary dysmenorrhea, research explored short-term symptom changes, focusing on outcomes related to measured symptom change during menstrual cycles.

What remains uncertain for fever research is that the studies focus strictly on immediate symptom resolution, offering limited insight into the long-term patterns of fever recurrence. For primary dysmenorrhea, data are still emerging for long-term outcomes of repeated use over many years.


Evidence for Exploring Symptoms of Inflammatory Conditions

Ibucare was evaluated in studies relevant to conditions associated with functional limitations, such as Osteoarthritis (OA). The research examined metrics such as functional capacity scores and patient and physician global assessments of symptoms, primarily through Intermediate-term RCTs and long-term observational settings.

Research describes findings related to patient and physician assessments of symptoms. A key limitation is that the long-term outcomes are not fully established regarding whether Ibucare affects the underlying structural course of chronic inflammatory diseases over many years. The available evidence is better suited for understanding symptom patterns over the short- to intermediate-term.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Ibucare (FAQ)


Q: What is the expected duration of the effects of Ibucare?

Regulatory documents state that dosing for Ibucare is typically repeated every 4 to 6 hours while symptoms persist. This guidance indicates that measured symptom relief is generally managed within this interval.


Q: Can Ibucare be taken long-term for chronic conditions?

Official warnings consistently emphasize that the lowest effective dosage should be used for the shortest possible duration. Official warnings note that serious risks are associated with both higher doses and longer duration of use.


Q: Why is it recommended to take Ibucare with food?

It is generally described in official drug information that taking Ibucare with food or milk can help reduce the possibility of stomach upset or other gastrointestinal complaints.


Q: Is there a maximum length of time Ibucare is generally used for?

For self-treatment, regulatory guidance specifies a duration limit: generally 10 days for pain and 3 days for fever. Use beyond these timeframes, particularly for chronic conditions, is a matter for consultation with a healthcare provider.


Q: What does the research say about Ibucare and cardiovascular health?

Official warnings mandate that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like Ibucare are associated with an increased risk of serious cardiovascular thrombotic events. This includes serious events such as myocardial infarction (heart attack) and stroke.


Q: How quickly can someone typically expect Ibucare to start working?

Official clinical pharmacology information indicates that the amount of the drug in the blood generally peaks one to two hours after administration. This timeframe generally indicates when the drug reaches its highest concentration in the bloodstream.


Q: Does taking Ibucare cause drowsiness or affect driving?

Dizziness and drowsiness are among the reported side effects listed in official documents. Official safety information notes that caution is required when driving or operating machinery until the individual's reaction to the medication is known.


Q: Is it true that Ibucare can affect the stomach?

Official warnings confirm that Ibucare is associated with potential effects on the gastrointestinal system. There is a documented risk of serious adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines.


Q: Do you need a prescription to get Ibucare?

Ibucare (ibuprofen) is available in most regions as both an Over-The-Counter (OTC) medicine and as a prescription-only product. The availability depends on the dosage strength, with higher doses typically requiring a prescription.


Q: What happens if I miss a time to take Ibucare?

Official guidance generally advises to take the missed dose as soon as you remember, unless it is already close to the time of your next scheduled dose. If so, official guidance generally advises to skip the missed dose and resume the regular schedule.


Q: Are there any common foods or drinks that interact with Ibucare?

Official drug information states that the amount of drug absorbed is only minimally altered by the presence of food, and it can be taken with food or milk. However, the consumption of alcohol is known to increase the risk of gastrointestinal bleeding.


Q: How is Ibucare different from aspirin?

Both are classified as NSAIDs, but Ibucare is chemically distinct from aspirin (acetylsalicylic acid). Regulatory documents note that Ibucare is contraindicated in patients who have experienced allergic-type reactions to aspirin and that the two drugs have different effects on the body.


Q: Is Ibucare the same as its generic name?

Ibucare is a brand name. The product's active ingredient is ibuprofen, which is the official generic name for the drug. This active ingredient is regulated by health authorities worldwide.


Q: What is the difference between prescription Ibucare and over-the-counter Ibucare?

The primary differences noted in official information relate to the dosage strength and the maximum allowed daily dose. Prescription strengths are typically higher than those available without a doctor's order.


Q: Can Ibucare cause a skin rash?

Yes, skin rash is a reported adverse reaction associated with the drug. In some cases, a rash can be a symptom of a serious hypersensitivity or allergic reaction.


Q: Does Ibucare contain gluten or lactose?

Official inactive ingredient lists for some formulations explicitly include lactose. Information regarding gluten status is generally not a required regulatory labeling component.


Q: Can Ibucare be taken when feeling generally unwell, or only for specific official uses?

Official indications describe Ibucare’s use for the temporary relief of minor aches and pains associated with specific common ailments (like the common cold, headaches, or toothaches) and for the temporary reduction of fever.


Q: How does the official information describe the risk of serious side effects from Ibucare?

Official warnings state that the risk of serious cardiovascular or gastrointestinal events may occur early in treatment and generally increases with both a longer duration of use and higher doses.


Q: What should be done if someone accidentally takes too much Ibucare?

Official guidance on suspected overdose recommends contacting a Poison Control Center or local emergency medical services for management instructions.


Q: Is it possible for Ibucare to cause mood changes?

Yes, mental or mood changes are listed in official product information as a possible, though less common, serious side effect that should be reported if experienced.


Q: Can Ibucare interact with cold or flu medicines?

Ibucare can be found in combination products used for cold and flu symptoms. However, official information notes that it can interact with specific types of cold medicines (e.g., MAO inhibitors). This highlights the need to check all product ingredients.


Q: Are there different strengths of Ibucare available?

Yes, regulatory authorities have approved several different strengths of the active ingredient, ibuprofen. These range from lower over-the-counter strengths (e.g., 200 mg) to higher prescription strengths (e.g., 400 mg, 600 mg, and 800 mg) for various needs.


Q: What is known about the use of Ibucare in people with asthma?

It is officially contraindicated for use in patients who have experienced asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs, as there is a documented risk of severe, serious reactions.


Q: How is Ibucare typically eliminated from the body?

According to official clinical information, the drug is quickly processed, or metabolized, by the liver. It is then eliminated from the body primarily in the urine in the form of inactive breakdown products.


Q: Can people with diabetes use Ibucare?

While diabetes is not an absolute contraindication, official drug information lists it as a condition that may require caution or monitoring during use. It is typically managed with a healthcare provider to minimize potential risks.


Q: Is Ibucare considered a narcotic or habit-forming?

Ibucare (ibuprofen) is classified by the Drug Enforcement Administration as having No DEA Schedule. This means it is not considered a controlled substance, nor is it classified as a narcotic or habit-forming drug under this classification.


Q: Can Ibucare be crushed or split?

Official guidance recommends that patients consult the package insert for their specific formulation. The crushing or splitting of certain forms, such as extended-release products, is typically not recommended.


Q: What is the official information regarding overdose symptoms for Ibucare?

Overdose symptoms can vary but may include severe headache, dizziness, a ringing in the ears, blurred vision, severe stomach pain, and vomiting. In severe cases, symptoms such as slow breathing or decreased consciousness have been reported.


How should Ibucare be stored and disposed of?

How to Store and Dispose of Ibucare?

To maintain product stability, Ibucare must be stored at room temperature, typically between 68 F and 77 F (20 C and 25 C). The medication must be protected from excess heat and moisture and should be kept away from freezing temperatures. Always keep the medicine in its original, tightly closed container.

A key requirement is child safety; the product must be stored locked up and out of the sight and reach of children and pets to prevent accidental ingestion.

For disposal of unused or expired medicine, the preferred method is to use a drug take-back program. If a take-back program is unavailable, mix the medicine with an unappealing substance, such as dirt or used coffee grounds, and place the mixture in a sealed plastic bag before discarding it in the household trash. Do not flush the medicine down the toilet or pour it down a drain unless specifically authorized by government regulation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibucare found in:

A-Z Index: